The Director-General of National Agency for Food and Drug
Administration and Control (NAFDAC), Professor Mojisola Adeyeye,
has said that the Agency does not have any control over which drug
to use or not to use for any particular ailment, including
remdesivir, which was initially developed for the treatment of
Ebola virus.
Prof Mojisola who made this remark on Sunday said that the
drug in question, remdesivir, though developed and tried for Ebola
in the past, is not commercially available yet.
It is likely to be very expensive and may not be available
immediately for African countries because of availability and
affordability.
She further pointed out that the current approach adopted by the
Federal Ministry of Health and other stakeholders in the treatment
of COVID-19 patients in the country appeared to be very
effective.
She provided more insight into the use of chloroquine and
hydroxychloroquine as well as their risk to benefit ratio.
The Director-General of National Agency for Food and Drug
Administration and Control (NAFDAC), Professor Mojisola Adeyeye,
has said that the Agency does not have any control over which drug
to use or not to use for any particular ailment, including
remdesivir, which was initially developed for the treatment of
Ebola virus.
Prof Mojisola who made this remark on Sunday said that the
drug in question, remdesivir, though developed and tried for Ebola
in the past, is not commercially available yet.
It is likely to be very expensive and may not be available
immediately for African countries because of availability and
affordability.
She further pointed out that the current approach adopted by the
Federal Ministry of Health and other stakeholders in the treatment
of COVID-19 patients in the country appeared to be very
effective.
She provided more insight into the use of chloroquine and
hydroxychloroquine as well as their risk to benefit ratio.